US Stock Insider Trading | Wanda Biopharmaceuticals disclosed one insider transaction on February 24

K-LinePoet · 2026-03-05T02:32:57+00:00

Wanda Biopharmaceuticals disclosed on February 24, 2026, that Director Honore Tage sold 30,000 shares on February 23, with a total transaction amount of $240,900. The company focuses on developing innovative therapies dedicated to meeting medical needs and improving patients' lives.

K-LinePoet

2026-03-05 02:32:57

Abstract generation in progress

On February 24, 2026, Wanda Biopharmaceuticals (VNDA) disclosed one insider transaction. Director Honore Tage sold 30,000 shares on February 23, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 24, 2026	Director	Honore Tage	February 23, 2026	Sell	30,000	8.03	240,900
August 8, 2025	Director	Polymeropoulos Mihael Hristos	August 7, 2025	Buy	10,000	4.15	41,500
June 16, 2025	Director	Mitchell Stephen Ray	June 13, 2025	Sell	7,000	4.59	32,100
May 21, 2025	Director	Polymeropoulos Mihael Hristos	May 21, 2025	Buy	481	4.39	2,111.59
May 21, 2025	Director	Polymeropoulos Mihael Hristos	May 21, 2025	Buy	9,519	4.40	41,900
May 19, 2025	Director	Polymeropoulos Mihael Hristos	May 16, 2025	Buy	20,000	4.22	84,500
March 6, 2025	Director	Polymeropoulos Mihael Hristos	March 6, 2025	Buy	5,000	5.02	25,100
March 6, 2025	Director	Polymeropoulos Mihael Hristos	March 6, 2025	Buy	5,000	5.01	25,100
March 5, 2025	Director	Polymeropoulos Mihael Hristos	March 5, 2025	Buy	5,000	5.03	25,100
March 5, 2025	Director	Polymeropoulos Mihael Hristos	March 5, 2025	Buy	5,000	5.01	25,100

[Company Profile]

Vanda Pharmaceuticals Inc. was incorporated in Delaware in 2002. The company is a leading global biopharmaceutical company focused on developing and commercializing innovative therapies to address unmet medical needs and improve patients’ lives. The company strives to advance new approaches by responsibly innovating to bring important new drugs to market. It is committed to using science-based technologies, including genetics and genomics, in drug discovery, clinical trials, and product commercialization.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.